Methyl-Hesperidin
Based on 1 Customer Validation
Methyl-Hesperidin is a glycoside compound. Methyl-Hesperidin has hypotensive, coronary dilating, smooth muscle relaxing, capillary stabilizing, choleretic, and anti-ulcer activities. Methyl-Hesperidin act as a competitive substrate to inhibit HIV-1 reverse transcriptase activity. Methyl-Hesperidin potentiates coronary dilating actions of adenine nucleotides and 3'-AMP, enhances depressant action on isolated atria, and prolongs adenosine- and ATP-induced heart block in guinea pigs.
For research use only. We do not sell to patients.
- Purity: 99.70%
- CAS No.: 11013-97-1
- Formula: C29H36O15
- Molecular Weight:624.59
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
HY-15337
Hesperidin
-
HY-N2118
Bilobetin
-
HY-N0376
Liquiritin
-
HY-N0512
Loganin
-
HY-N0112
Dihydromyricetin
-
HY-N0165R
Methyl-Hesperidin (Standard)
-
HY-15337R
Hesperidin (Standard)
-
HY-N0112R
Dihydromyricetin (Standard)
-
HY-N1461
Dihydrodaidzein
-
HY-N8495
4'-Hydroxyflavanone
-
HY-Y0278
Chloranil
-
HY-N0512R
Loganin (Standard)
Biological Activity
|
HIV-1 |
Methyl hesperidin binds to HIV-1 reverse transcriptase with a binding energy of -8.8 kcal/mol via multiple interaction types, indicating it has affinity for the enzyme and could act as a competitive substrate to inhibit HIV-1 reverse transcriptase activity[1].
Methyl-Hesperidin (2×10-5-1×10-3 M) does not meaningfully inhibit calf intestine-derived adenosine deaminase activity, with inhibition percentages ranging from 0.2-2.6%[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Methyl-Hesperidin (1.0-2.5 mg/kg; i.v.; single injection) dose-dependently prolongs the duration of adenosine- and ATP-induced heart block in guinea pigs, with no effect on acetylcholine-induced block[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:nembutalized (anesthetized, open-chest)[2]
-
Dosage:0.5 mg/kg/min
-
Administration:i.v.; continuous infusion; single administration
-
Result:Markedly potentiated the coronary dilating action of 3'-AMP, as measured by increased left coronary blood flow (CF) in recorded tracings.
-
Animal Model:Guinea pigs[2]
-
Dosage:1.0 mg/kg; 2.5 mg/kg
-
Administration:i.v.; single injection
-
Result:Increased the percent change in adenosine-induced heart block duration to 254% at 1-2 minutes post-administration, 197% at 4 minutes, 172% at 7 minutes, 168% at 10 minutes, and 143% at 12-17 minutes (1.0 mg/kg dose).
Increased the percent change in adenosine-induced heart block duration to 400% at 1-2 minutes post-administration, 344% at 4 minutes, 238% at 7 minutes, 224% at 10 minutes, and 198% at 12-17 minutes (2.5 mg/kg dose).
Prolonged ATP-induced heart block to a similar degree as adenosine-induced block.
Did not affect acetylcholine-induced heart block at the 2.5 mg/kg dose.
Chemical Information
-
CAS No. 11013-97-1
-
Appearance Solid
-
Molecular Weight 624.59
-
Formula C29H36O15
-
Color White to light yellow
-
SMILES
O=C1C[C@@H](C2=CC=C(OC)C(O)=C2)OC3=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]5[C@@H]([C@@H]([C@H]([C@H](C)O5)O)O)O)O4)O)O)O)=CC(OC)=C13.O=C6C[C@@H](C7=CC=C(OC)C(OC)=C7)OC8=CC(O[C@H]9[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]%10[C@@H]([C@@H]([C@H]([C@H](C)O%10)O)O)O)O9)O)O)O)=CC(O)=C68
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Solvent & Solubility
DMSO : 100 mg/mL (160.11 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.00 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6011 mL | 8.0053 mL | 16.0105 mL | 40.0263 mL |
| 5 mM | 0.3202 mL | 1.6011 mL | 3.2021 mL | 8.0053 mL | |
| 10 mM | 0.1601 mL | 0.8005 mL | 1.6011 mL | 4.0026 mL | |
| 15 mM | 0.1067 mL | 0.5337 mL | 1.0674 mL | 2.6684 mL | |
| 20 mM | 0.0801 mL | 0.4003 mL | 0.8005 mL | 2.0013 mL | |
| 25 mM | 0.0640 mL | 0.3202 mL | 0.6404 mL | 1.6011 mL | |
| 30 mM | 0.0534 mL | 0.2668 mL | 0.5337 mL | 1.3342 mL | |
| 40 mM | 0.0400 mL | 0.2001 mL | 0.4003 mL | 1.0007 mL | |
| 50 mM | 0.0320 mL | 0.1601 mL | 0.3202 mL | 0.8005 mL | |
| 60 mM | 0.0267 mL | 0.1334 mL | 0.2668 mL | 0.6671 mL | |
| 80 mM | 0.0200 mL | 0.1001 mL | 0.2001 mL | 0.5003 mL | |
| 100 mM | 0.0160 mL | 0.0801 mL | 0.1601 mL | 0.4003 mL |
Methyl-Hesperidin Related Classifications
HY-N0165 Related Classifications
Powered by Bioz